R&D at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s R&D?
- Relmada Therapeutics, Inc. (RLMD) reported R&D of $8.09M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s R&D changed year-over-year?
- Relmada Therapeutics, Inc.'s R&D decreased by 32.3% year-over-year, from $11.95M to $8.09M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s R&D has grown at a -26.2% compound annual growth rate (CAGR), from $90.62M to $26.88M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.